PANTHERx® Rare Selected for Distribution of Crenessity™ by Neurocrine Biosciences, Transforming CAH Treatment
In a significant move aimed at improving patient care for congenital adrenal hyperplasia (CAH), Neurocrine Biosciences, Inc. has appointed PANTHERx® Rare as the exclusive specialty pharmacy for its groundbreaking medication, CRENESSITY™ (crinecerfont). This oral, selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist is designed to aid in androgen control while reducing glucocorticoid doses for pediatric patients aged four and above.
CRENESSITY™ marks a pivotal progression in the management of classic CAH, becoming the first non-steroidal treatment approved for this condition. CAH is a rare genetic disorder, primarily caused by a deficiency of the enzyme 21-hydroxylase, responsible for adrenal hormone production. This deficiency can lead to inadequate cortisol and aldosterone levels, resulting in the overproduction of androgens. Symptoms can include anxiety, hirsutism, atypical genital development, and fertility challenges, significantly impacting the quality of life for those affected.
Rob Snyder, Executive Chair of PANTHERx® Rare, expressed pride in the partnership with Neurocrine Biosciences. He emphasized the pharmacy’s commitment to providing tailored support and accessibility to life-altering therapies for patients facing rare and complex diseases. The collaboration highlights PANTHERx’s ongoing dedication to serving the rare disease community, which includes approximately 25-30 million Americans and over 7,000 recognized rare conditions.
With more than 90% of rare diseases lacking an FDA-approved treatment, this strategic partnership is positioned to transform the landscape of therapy for conditions like CAH. As PANTHERx continues to deliver innovative solutions and support for patients, the introduction of CRENESSITY™ represents a beacon of hope. The dual-accredited pharmacy holds an esteemed reputation, being a six-time recipient of the MMIT Patient Choice Award, demonstrating their focus on patient satisfaction.
As the healthcare community eagerly anticipates the improved patient outcomes that CRENESSITY™ may bring, it is crucial to highlight the role of partnerships in the rare disease sector. With Policymakers and scientists increasingly recognizing the need for orphan drug approvals, advancements in treatment options are becoming more accessible. The partnership between Neurocrine Biosciences and PANTHERx® Rare exemplifies the collaborative efforts necessary to address the unmet needs of patients living with rare diseases.
PANTHERx Rare’s headquarters in Pittsburgh, Pennsylvania, licenses operations across all 50 states and U.S. territories. Their accreditation in orphan drug distributions further emphasizes their commitment to excellence in patient care. This partnership not only aims to improve health outcomes but also strives to create a more inclusive healthcare environment for those fighting rare diseases.
For individuals affected by CAH, the journey towards better health takes a significant step forward with the introduction of CRENESSITY™. With tailored solutions and dedicated support from PANTHERx® Rare, the future holds promise for transformative changes in the lives of many who have long been underserved in the healthcare system.
CRENESSITY™ marks a pivotal progression in the management of classic CAH, becoming the first non-steroidal treatment approved for this condition. CAH is a rare genetic disorder, primarily caused by a deficiency of the enzyme 21-hydroxylase, responsible for adrenal hormone production. This deficiency can lead to inadequate cortisol and aldosterone levels, resulting in the overproduction of androgens. Symptoms can include anxiety, hirsutism, atypical genital development, and fertility challenges, significantly impacting the quality of life for those affected.
Rob Snyder, Executive Chair of PANTHERx® Rare, expressed pride in the partnership with Neurocrine Biosciences. He emphasized the pharmacy’s commitment to providing tailored support and accessibility to life-altering therapies for patients facing rare and complex diseases. The collaboration highlights PANTHERx’s ongoing dedication to serving the rare disease community, which includes approximately 25-30 million Americans and over 7,000 recognized rare conditions.
With more than 90% of rare diseases lacking an FDA-approved treatment, this strategic partnership is positioned to transform the landscape of therapy for conditions like CAH. As PANTHERx continues to deliver innovative solutions and support for patients, the introduction of CRENESSITY™ represents a beacon of hope. The dual-accredited pharmacy holds an esteemed reputation, being a six-time recipient of the MMIT Patient Choice Award, demonstrating their focus on patient satisfaction.
As the healthcare community eagerly anticipates the improved patient outcomes that CRENESSITY™ may bring, it is crucial to highlight the role of partnerships in the rare disease sector. With Policymakers and scientists increasingly recognizing the need for orphan drug approvals, advancements in treatment options are becoming more accessible. The partnership between Neurocrine Biosciences and PANTHERx® Rare exemplifies the collaborative efforts necessary to address the unmet needs of patients living with rare diseases.
PANTHERx Rare’s headquarters in Pittsburgh, Pennsylvania, licenses operations across all 50 states and U.S. territories. Their accreditation in orphan drug distributions further emphasizes their commitment to excellence in patient care. This partnership not only aims to improve health outcomes but also strives to create a more inclusive healthcare environment for those fighting rare diseases.
For individuals affected by CAH, the journey towards better health takes a significant step forward with the introduction of CRENESSITY™. With tailored solutions and dedicated support from PANTHERx® Rare, the future holds promise for transformative changes in the lives of many who have long been underserved in the healthcare system.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.